Global specialty pharmaceutical company sought cross-functional alignment on epidemiological figures in order to have a global common base to assess business opportunities.
CRA approach
- Review evidence from client and augment with review of available scientific literature
- Developed a disease-progression model for each disease to calculate size of subpopulations (mutated, symptomatic, treatment eligible) for which reliable data was lacking
- Led live workshops with cross-functional client team to review and select best evidence, methodology, and sanity check of results
Client impact
- Documentation of results for executive level and for communication to regional level
- Evaluation of impact on assumed patient population numbers
- Understanding of impact of knowledge gaps and of methodology and ideal frequency to review
